| Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ... Science 348 (6230), 124-128, 2015 | 8010 | 2015 |
| Comprehensive molecular characterization of human colon and rectal cancer Cancer Genome Atlas Network Nature 487 (7407), 330, 2012 | 7382 | 2012 |
| Genetic basis for clinical response to CTLA-4 blockade in melanoma A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ... New England Journal of Medicine 371 (23), 2189-2199, 2014 | 4448 | 2014 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4347 | 2018 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3068 | 2019 |
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 2955 | 2016 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 2544 | 2018 |
| Integrated genomic characterization of papillary thyroid carcinoma N Agrawal, R Akbani, BA Aksoy, A Ally, H Arachchi, SL Asa, JT Auman, ... Cell 159 (3), 676-690, 2014 | 2482 | 2014 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2400 | 2018 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2135 | 2018 |
| IDH mutation impairs histone demethylation and results in a block to cell differentiation C Lu, PS Ward, GS Kapoor, D Rohle, S Turcan, O Abdel-Wahab, ... Nature 483 (7390), 474-478, 2012 | 2131 | 2012 |
| IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype S Turcan, D Rohle, A Goenka, LA Walsh, F Fang, E Yilmaz, C Campos, ... Nature 483 (7390), 479-483, 2012 | 2105 | 2012 |
| Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ... Annals of Oncology 30 (1), 44-56, 2019 | 2007 | 2019 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2002 | 2018 |
| The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy JJ Havel, D Chowell, TA Chan Nature Reviews Cancer 19 (3), 133-150, 2019 | 1911 | 2019 |
| CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy W Wang, M Green, JE Choi, M Gijón, PD Kennedy, JK Johnson, P Liao, ... Nature 569 (7755), 270-274, 2019 | 1734 | 2019 |
| Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses KB Chiappinelli, PL Strissel, A Desrichard, H Li, C Henke, B Akman, ... Cell 162 (5), 974-986, 2015 | 1704 | 2015 |
| Tumor and microenvironment evolution during immunotherapy with nivolumab N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ... Cell 171 (4), 934-949. e16, 2017 | 1703 | 2017 |
| Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1555 | 2018 |
| PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs TC He, TA Chan, B Vogelstein, KW Kinzler Cell 99 (3), 335-345, 1999 | 1502 | 1999 |
Luc MorrisMSKCCVerified email at mskcc.org
